NEW YORK (GenomeWeb News) – PerkinElmer has licensed photon detection technology developed by the Max Planck Institute for use in a range of molecular imaging applications, the Waltham, Mass.-based company said today.

Under the exclusive agreement with Max Planck Innovation, the Max Planck Institute's technology transfer arm, the company has licensed solid state silicon photomultiplier, or SiPM, technology that it will use in clinical diagnostics, as well as molecular detection and analytical applications, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.